Sign Up Today and Learn More About Bigfoot Biomedical Stock

Invest in or calculate the value of your shares in Bigfoot Biomedical or other pre-IPO companies through EquityZen's platform.

Get Started

Bigfoot Biomedical Stock

Medical Device Company

About Bigfoot Biomedical Stock

Founded

2014

Headquarters

Milpitas, CA, US

Notable Investor

Cormorant Asset Management

Total Funding

92.5M

Bigfoot Biomedical is a medical device company changing diabetes care for people with insulin-requiring diabetes. The company developing an end-to-end type 1 diabetes management system using a simple design, cloud connectivity, and human-centered automation. It optimizes the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care. Biofoot Biomedical ’s pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. By employing data-driven intelligence across an integrated device ecosystem, they are transforming diabetes care with a fully comprehensive digital drug delivery platform experienced as a service.

Investors in Bigfoot Biomedical

Discover investors in Bigfoot Biomedical stock and explore their portfolio companies

Bigfoot Biomedical Management

Leadership team at Bigfoot Biomedical

Chief Executive Officer

Brewer Jeffrey

Chief Financial Officer

Brett Hale

Locked Features

Join now and verify your accreditation status to gain access to:

  • Bigfoot Biomedical current valuation
  • Bigfoot Biomedical stock price
  • Available deals in Bigfoot Biomedical and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Bigfoot Biomedical stock?

Accredited investors can buy pre-IPO stock in companies like Bigfoot Biomedical through EquityZen funds. These investments are made available by existing Bigfoot Biomedical shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Bigfoot Biomedical stock?

Shareholders can sell their Bigfoot Biomedical stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."